A combination of Mirati Therapeutics Inc.’s genetic mutation-targeting adagrasib and Eli Lilly and Co.’s older cancer drug Erbitux shrank tumors in 39 percent of patients with advanced colorectal cancer treated in a small trial, the company said on Sept. 19.
Phathom Pharmaceuticals Inc. submitted two new drug applications (NDAs) to the U.S. Food and Drug Administration for the use of vonoprazan in combination with amoxicillin and clarithromycin (vonoprazan triple therapy) and vonoprazan in combination with amoxicillin (vonoprazan dual therapy) as a treatment for Helicobacter pylori infection in adults.
The U.S. Food and Drug Administration expanded the emergency use authorization of Regeneron Pharmaceuticals Inc.’s Covid-19 antibody cocktail, enabling the combo therapy’s use as a preventive treatment for the illness in certain people.
California-based biopharmaceutical firm BridgeBio Pharma announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers.
The U.S. Food and Drug Administration greenlit the classification of California-based biotechnology firm Genentech’s Venclexta (venetoclax) and azicitidine combination as a Breakthrough Therapy Drug.
Positive results from Sellas Life Sciences Group’s Phase I/II trial using galinpepimut-S (GPS) as a combination therapy with pembrolizumab (Keytruda) were announced shortly after similarly positive news was issued from a combination study in which GPS was evaluated as a treatment for mesothelioma.
George Medicines announced the initiation of two Phase III trials investigating the late-stage drug development company’s proprietary triple combination candidate, GMRx2, as a first-line treatment for hypertension.
On June 5, the United States and the rest of the world marks a grim milestone – the 40th anniversary of the HIV epidemic. While the virus has taken the lives of an estimated 35 million people over the last 40 years, an end could be in sight as biopharma researchers continue to develop safe and effective new treatments, with an eye toward a potential cure.
An experimental Bristol Myers Squibb drug from a new class of immunotherapy used in combination with the company’s big-selling cancer medicine Opdivo significantly extended the time it took for advanced melanoma to worsen compared with Opdivo alone, according to early data from a study released on May 19.
Bausch Health Companies and Ortho Dermatologics announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating the investigational medicine IDP-126, a combination retinoid, anti-bacterial and antibiotic topical to treat acne vulgaris in patients 9 years of age and older.